Peak Bio, Inc.

Peak Bio, Inc. (Nasdaq: PKBO) is a clinical-stage biopharmaceutical company that entered the public markets through a de-SPAC merger with Ignyte Acquisition Corp., a blank-check vehicle sponsored by Ignyte Sponsor LLC that completed its initial public offering in 2021 targeting the healthcare and life sciences sector. Peak Bio is focused on developing differentiated therapeutic candidates for oncology and inflammatory diseases. The S-1/A amendment filed February 1, 2023, under accession number 0001193125-23-020523, represents a post-combination registration statement update with the Securities and Exchange Commission. For comprehensive filing history, deal metrics, and real-time SPAC analytics on PKBO and the broader SPAC universe, sign up for full data access at SpacDesk.